$168 Million is the total value of Abingworth LLP's 16 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRSP | Crisprnamen akt | $54,858,000 | -24.5% | 1,237,202 | 0.0% | 32.62% | -21.5% | |
| PRTK | Paratek | $10,047,000 | -4.9% | 1,041,131 | 0.0% | 5.97% | -1.1% | |
| OBSV | Obseva | $7,938,000 | +19.2% | 440,000 | 0.0% | 4.72% | +24.0% | |
| CHMA | Chiasma | $7,490,000 | +140.0% | 2,080,595 | 0.0% | 4.45% | +149.7% | |
| PRTO | Proteon | $3,834,000 | -20.8% | 2,017,872 | 0.0% | 2.28% | -17.6% | |
| ADAP | Adaptimmunesponds adr | $3,390,000 | +14.3% | 250,000 | 0.0% | 2.02% | +18.9% | |
| CBAY | Cymabay | $3,027,000 | -17.5% | 273,417 | 0.0% | 1.80% | -14.1% | |
| RARE | Ultragenyx | $2,910,000 | -0.6% | 38,100 | 0.0% | 1.73% | +3.4% | |
| CLLS | Cellectissponds adr | $2,823,000 | -0.1% | 100,000 | 0.0% | 1.68% | +4.0% | |
| AUPH | Aurinia Pharma | $2,655,000 | +18.0% | 400,434 | 0.0% | 1.58% | +22.8% | |
| SRRA | Sierra Oncology | $2,456,000 | -42.6% | 1,444,445 | 0.0% | 1.46% | -40.2% | |
| AVEO | Aveo Pharma | $1,316,000 | +46.2% | 400,000 | 0.0% | 0.78% | +52.1% | |
| IMDZ | Immune Design | $1,198,000 | -26.1% | 352,300 | 0.0% | 0.71% | -23.1% | |
| HSGX | Histogenix | $473,000 | -78.5% | 888,889 | 0.0% | 0.28% | -77.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-05-03 |
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
| 13F-HR | 2023-02-10 |
| 4 | 2023-01-31 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.